

written notifications disclosing all changes in membership.

On May 28, 2009, Pistoia Alliance, Inc. filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on July 15, 2009 (74 FR 34364).

The last notification was filed with the Department on February 28, 2022. A corrected notice was published in the **Federal Register** pursuant to section 6(b) of the Act on July 20, 2022 (87 FR 43298).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics, Antitrust Division.*

[FR Doc. 2022-18817 Filed 8-30-22; 8:45 am]

**BILLING CODE 4410-11-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-1072]

#### Importer of Controlled Substances Application: Experic LLC

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Experic LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 30, 2022. Such persons may also file a written request for a hearing on the application on or before September 30, 2022.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no

need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on July 7, 2022, Experic LLC, 2 Clarke Drive, Cranbury, New Jersey 08512-3619, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana Extract ....	7350	I
Marihuana .....	7360	I
Tetrahydrocannabinols.	7370	I
Psilocybin .....	7437	I
5-Methoxy-N-N-Dimethyltryptamine.	7431	I
Psilocyn .....	7438	I
Nabilone .....	7379	II

The company plans to import drug code 7437 (Psilocybin) and Psilocyn (7438) as bulk powder and Marihuana Extract (7350), Marihuana (7360) Tetrahydrocannabinols (7370) and Nabilone (7379) as finished dosage units for research and clinical trial purposes. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2).

Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Kristi O'Malley,**

*Assistant Administrator.*

[FR Doc. 2022-18744 Filed 8-30-22; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-372]

#### Exempt Chemical Preparations Under the Controlled Substances Act

**AGENCY:** Drug Enforcement Administration, Department of Justice.

**ACTION:** Order with opportunity for comment.

**SUMMARY:** The applications for exempt chemical preparations received by the Drug Enforcement Administration (DEA) between August 30, 2021, and March 31, 2022, as listed below, were accepted for filing and have been approved or denied as indicated.

**DATES:** Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). Electronic comments must be submitted, and written comments must be postmarked, on or before October 31, 2022. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. eastern time on the last day of the comment period.

**ADDRESSES:** To ensure proper handling of comments, please reference "Docket No. DEA-372" on all correspondence, including any attachments.

*Electronic comments:* DEA encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to <http://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on *Regulations.gov*. If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment.

*Paper comments:* Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment *in lieu of* an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**FOR FURTHER INFORMATION CONTACT:** Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (571) 362-8201.

#### SUPPLEMENTARY INFORMATION:

##### Posting of Public Comments

Please note that all comments received are considered part of the public record and made available for public inspection online at <http://www.regulations.gov>

[www.regulations.gov](http://www.regulations.gov) and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act applies to all comments received.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information and confidential business information identified as directed above will generally be made publicly available in redacted form. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to <http://www.regulations.gov> may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at <http://www.regulations.gov> for easy reference.

### Legal Authority

Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements

detailed in 21 U.S.C. 811(g)(3)(B).<sup>1</sup> The Drug Enforcement Administration (DEA) regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

### Exempt Chemical Preparation Applications Submitted Between August 30, 2021, and March 31, 2022

DEA received applications between August 30, 2021, and March 31, 2022, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects, if abused, and so that the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and

specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822–823, 825–829, and 952–954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters.

### Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those above mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)–(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)–(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunity for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities.

Additional exempt chemical preparation requests received between August 30, 2021, and March 31, 2022, and not otherwise referenced in this order, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future **Federal Register** publication.

DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957.

<sup>1</sup> This authority has been delegated from the Attorney General to the DEA Administrator by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and section 7 of the appendix to subpart R of part 0.

## CHART I

Supplier	Product name	Form	Application date
Aalto Scientific, Ltd	Unassayed Chemistry Base Level 1	Glass or plastic bottle or flask: 1mL–100 mL; 100mL–500mL; 500mL–1L.	3/28/2022
Aalto Scientific, Ltd	Unassayed Chemistry Base Level 2	Glass or plastic bottle or flask: 1mL–100 mL; 100mL–500mL; 500mL–1L.	3/28/2022
Aalto Scientific, Ltd	Unassayed Chemistry Base Level 3	Glass or plastic bottle or flask: 1mL–100 mL; 100mL–500mL; 500mL–1L.	3/28/2022
Absolute Standards, Inc	(-)- $\Delta$ 8-THC-D3, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(-)- $\Delta$ 9-THC-D3, 100 ug/mL, in Ethanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(-)- $\Delta$ 9-THC-D3, 1000 ug/mL, in Ethanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-11-Hydroxy- $\Delta$ 9-THC-D3, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-11-Hydroxy- $\Delta$ 9-THC-D3, 1000 ug/mL, in Methanol.	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-Amphetamine-D8, 10 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-Amphetamine-D8, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-Amphetamine-D8, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-Methamphetamine-D8, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-Methamphetamine-D8, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	(+/-)-Methamphetamine-D9, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AB-CHMINACA, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AB-FUBINACA, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AB-PINACA, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AH-7921, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AKB48 (APINACA), 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	alpha-Pyrrolidinobutiophenone (alpha-PBP), 100 ug/mL, in Methanol.	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AM2201, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	AM2201, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Benzoylecgonine, 10 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Benzoylecgonine, 100 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Benzoylecgonine, 1000 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Benzoylecgonine-D8, 100 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Benzoylecgonine-D8, 1000 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Cocaine-D3, 10 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Cocaine-D3, 100 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Cocaine-D3, 1000 ug/ml, in Methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Codeine-6- $\beta$ -glucuronide, 10 ug/ml, in acetone:trile:water [1:1].	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Codeine-6- $\beta$ -glucuronide, 100 ug/ml, in acetone:trile:water [1:1].	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Codeine-6- $\beta$ -glucuronide, 1000 ug/ml, in acetone:trile:water [1:1].	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-MDEA, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-MDEA, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-MDEA, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-Methadone, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-Methadone, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-Methadone, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-Methadone-D3, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-Methadone-D3, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d,l-Methadone-D3, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	DBP Mix, 100 ug/ml, in MTBE	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	DBP Mix, 100 ug/ml, in MTBE	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Dimethyltryptamine, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Dimethyltryptamine, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	d-Propoxyphene, 100 ug/ml, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	d-Propoxyphene, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Ecognine methyl ester, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Ecognine methyl ester, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Ecognine methyl ester, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	EPA Method 551 "Mix B", 1000 ug/ml, in MTBE	Glass ampoule: 1 ml x 5	1/10/2022
Absolute Standards, Inc	EPA Method 551—Disinfection By-Products Mix #2, 100 ug/ml, in MTBE.	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	EPA Method 551.1—Analytes Mix #2, 100 ug/ml, in MTBE.	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Fenproporex, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022

## CHART I—Continued

Supplier	Product name	Form	Application date
Absolute Standards, Inc	Fenproporex-D5, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	FUB-144, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	FUB-AKB48 (FUB-APINACA), 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Heroin-D9, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Heroin-D9, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Heroin-D9, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydrocodone (+)-bitartrate salt, 100 ug/ml, in methanol.	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydrocodone (+)-bitartrate salt, 1000 ug/ml, in methanol.	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydrocodone, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydrocodone, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydrocodone, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydromorphone, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Hydromorphone, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	JWH-019, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-073, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-073, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-081, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-122, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-200, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-200-d5, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	JWH-250, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Ketamine, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Ketamine, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Ketamine-D4, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Lysergic acid diethylamide (LSD), 100 ug/mL, in Acetonitrile.	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Lysergic acid diethylamide (LSD), 100 ug/mL, in Acetonitrile.	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Lysergic acid diethylamide (LSD), 1000 ug/mL, in Acetonitrile.	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Lysergic acid diethylamide (LSD), 1000 ug/mL, in Acetonitrile.	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Meperidine, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Meperidine, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Meperidine, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Mephedrone, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Mephedrone, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Mix A, 1000 ug/ml, in MTBE	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	MMB-FUBINACA, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	MMB-FUBINACA, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Nitrazepam, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Nitrazepam, 1000 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	NM2201, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxazepam, 10 ug/ml, in acetonitrile	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxazepam, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxazepam, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxazepam, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxycodone, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxycodone, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxycodone, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Oxycodone-D3, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxycodone-D3, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxycodone-D6, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxycodone-D6, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxymorphone, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxymorphone, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxymorphone-D3, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Oxymorphone-D3, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	PB-22, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Phencyclidine-D5, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Phencyclidine-D5, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Phenylacetone, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Pregabalin, 10 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Pregabalin, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Pregabalin, 1000 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Psilocin, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Psilocin, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Psilocybin PT, varied ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	RCS-4, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022

## CHART I—Continued

Supplier	Product name	Form	Application date
Absolute Standards, Inc	THC-O-acetate, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	THC-O-acetate, 1000 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	THC-O-acetate, varied ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Tramadol, 10 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	Tramadol, 100 ug/ml, in methanol	Glass ampoule: 1 ml	1/10/2022
Absolute Standards, Inc	UR-144, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	XLR-11, 100 ug/mL, in Methanol	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Zopiclone, 100 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Absolute Standards, Inc	Zopiclone, 1000 ug/mL, in Acetonitrile	Glass ampoule: 1 mL	2/14/2022
Audit MicroControls, Inc	Control FLQ Unassayed Chemistry, Level 1	Kit: 10 bottles, 4 mL each	3/30/2022
Audit MicroControls, Inc	Control FLQ Unassayed Chemistry, Level 1	Kit: 5 bottles, 4 mL each	3/30/2022
Audit MicroControls, Inc	Control FLQ Unassayed Chemistry, Level 1	Plastic bottle: 4mL	3/30/2022
Cerilliant Corporation	(6aR,9R)-delta10-THC	Glass ampule: 1.0 mL	8/30/2021
Cerilliant Corporation	5 Part Potency in Beverage	Glass ampule: 1.0 mL	2/22/2022
Cerilliant Corporation	6 Part Potency in Solution (Acids)	Glass ampule: 1.0 mL	1/11/2022
Cerilliant Corporation	8 Part Potency in Solution (Neutrals)	Glass ampule: 1.0 mL	1/11/2022
Chemtos, LLC	(S)-N,N-dimethylamphetamine HCl (1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	(S)-N,N-dimethylamphetamine-d3 HCl (0.1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	(S)-N,N-dimethylamphetamine-d3 HCl (1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	2,4-DMMC HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	3,4-DMMC HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	3-MMC HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	4-CI-PVP HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	4-Methylbuphedrone (4-Me-MABP) HCl (1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	5F-MDMB-PICA (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	AB-CHMINACA (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	AB-PINACA (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	alpha-PHP HBr (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Alphaprodine HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Alphaprodine-d5 HCl (0.1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Alphaprodine-d5 HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	AM-694 (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Anileridine HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	APINACA, AKB48 (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	bk-MDDMA HCl (Dimethylone) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Diethyltryptamine (DET) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Dimethyltryptamine (DMT) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Dimethyltryptamine-d3 (DMT-d3) (0.1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Dimethyltryptamine-d3 (DMT-d3) (1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Dipentylone HCl (bk-DMBDP) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Estazolam (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Estazolam-d5 (0.1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Estazolam-d5 (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Flunitrazepam (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Flunitrazepam-d3 (0.1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Flunitrazepam-d3 (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Ketamine HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Ketamine-d4 HCl (0.1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Ketamine-d4 HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	MAB-CHMINACA (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	MDMB-CHMICA, MMB-CHMINACA (1 mg/mL in acetonitrile).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	MMB-CHMICA, AMB-CHMICA (1 mg/mL in acetonitrile).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	MPHP HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Naphyrone HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	N-Ethyl-amphetamine HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	N-Ethyl-amphetamine-d5 HCl (0.1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	N-ethylhexedrone (NEH) HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	N-ethylhexedrone-d5 (NEH-d5) HCl (0.1 mg/mL in methanol).	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	NM2201, CBL-2201 (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	PCC (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Phendimetrazine-d8 (0.1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Phendimetrazine-d8 (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022

## CHART I—Continued

Supplier	Product name	Form	Application date
Chemtos, LLC	Phenylacetone (1 mg/mL in acetonitrile)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Propylone HCl (bk-3,4-MDPA) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	PV8 (PHPP) HCl (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	Tenocyclidine (TCP) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
Chemtos, LLC	THJ-2201 (AM2201) (1 mg/mL in methanol)	Amber ampule: 1 mL	3/14/2022
CPI International	Custom Hormone Mix, 9-072, 1000 mg/L, 1 mL (ISO 17025).	Amber ampule: 1 mL	2/2/2022
LabSystems Diagnostics	NeoMass CAH Extraction Solution with Internal Standard.	Glass vial: 33 mL	1/10/2022
LabSystems Diagnostics	NeoMass CAH Multilevel Calibrator Dried Blood Spot Calibrator Level 0–7.	Aluminum pouch: 7 Dried blood spots, 85 µL each.	1/10/2022
LabSystems Diagnostics	NeoMass CAH Multilevel Controls Dried Blood Spot Controls Level 1–3.	Aluminum pouch: 6 Dried blood spots, 85 µL each.	1/10/2022
LabSystems Diagnostics	NeoMass CAH System suitability Mixture CAH (lyophilized).	Glass vial: 2 mL	1/10/2022
LabSystems Diagnostics	NeoMass CAH Tuning Mixture CAH (lyophilized)	Glass vial: 2 mL	1/10/2022
LGC	Narcotics Mixture 1 0.02–0.075 µg/mL in Synthetic oral fluid.	1 kit; 10 × 1 mL amber cryule.	3/8/2022
LGC	Narcotics Mixture 2 0.01–0.05 µg/mL in Synthetic oral fluid.	1 kit; 10 × 1 mL amber cryule.	3/8/2022
LGC	Narcotics Mixture 3 0.001–0.01 µg/mL in Synthetic oral fluid.	1 kit; 10 × 1 mL amber cryule.	3/8/2022
LGC—Dr. Ehrenstorfer	(6aR,9R)-Δ10-Tetrahydrocannabinol 100 µg/mL in Methanol.	Amber Ampule: 1 mL	12/21/2021
LGC—Dr. Ehrenstorfer	(6aR-trans)-Δ8-Tetrahydrocannabinol acetate 100 µg/mL in Methanol.	Amber Ampule: 1 mL	12/21/2021
LGC—Dr. Ehrenstorfer	Custom Cannabinoid Mixture 10141 1000 ug/mL in Acetonitrile.	Amber ampule: 1 mL	3/4/2022
LGC—Dr. Ehrenstorfer	Custom Cannabinoid Mixture 10142 1000 ug/mL in Acetonitrile.	1 kit; 5 × 1 mL amber ampule.	3/4/2022
LGC—Dr. Ehrenstorfer	Custom Pharmaceutical Mixture 10147 1000 ug/mL in Acetonitrile.	Amber ampule: 1 mL	3/4/2022
LGC—Dr. Ehrenstorfer	Custom Pharmaceutical Mixture 10148 1000 ug/mL in Acetonitrile.	1 kit; 5 × 1 mL amber ampule.	3/4/2022
LGC—Dr. Ehrenstorfer	Custom Tramadol hydrochloride 100 µg/mL in Methanol.	Glass Ampule: 1 mL	1/27/2022
LGC—Dr. Ehrenstorfer	Trenbolone cyclohexylmethylcarbonate 100 µg/mL in Acetonitrile.	Amber Ampule: 1 mL	12/21/2021
LGC—Dr. Ehrenstorfer	Zolpidem tartrate 100 µg/mL in Methanol	Glass Ampule: 1 mL	1/27/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab WrkBlk—Level 1	Volumetric flask: 200–8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 ab WrkBlk—Level 5	Volumetric flask: 200–8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re WrkBlk—Level 1	Volumetric flask: 200–8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	Fertility 1 re WrkBlk—Level 5	Volumetric flask: 200–8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ab Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ab Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ab Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ab Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ab Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ab WrkBlk—Level 1	Volumetric flask: 200–8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au WrkBlk—Level 1	Volumetric flask: 200–8000 mL.	3/21/2022

## CHART I—Continued

Supplier	Product name	Form	Application date
LGC Clinical Diagnostics, Inc	TDM1 bc Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 bc Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 bc Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 bc Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 bc Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 bc WrkBlk—Level 1	Volumetric flask: 200–8000 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db WrkBlk—Level 1	Volumetric flask: 200–8000 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set WrkBlk—Level 1	Volumetric flask: 200–8000 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set WrkBlk—Level 1	Volumetric flask: 200–8000 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set Bulk—Level 1	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set Bulk—Level 2	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set Bulk—Level 3	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set Bulk—Level 4	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set Bulk—Level 5	Volumetric flask: 3200 mL	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set WrkBlk—Level 1	Volumetric flask: 200–8000 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Testosterone (TSTO) Stock A 100,000 ng/ml	Plastic vial: 25 mL	3/21/2022
LGC Clinical Diagnostics, Inc	Testosterone (TSTO) Stock B 2,000 ng/ml	Plastic vial: 25 mL	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE Fertility 1 Test Set 502ab	5 Bottles: 4 mL each	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE Fertility 1 Test Set 502re	5 Bottles: 4 mL each	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE TDM1 Test Set 301ab	Kit: 5 Bottles, 3 ml each	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE TDM1 Test Set 301au	Kit: 5 Bottles, 3 ml each	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE TDM1 Test Set 301bc	Kit: 5 Bottles, 3 ml each	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE TDM1 Test Set 301db	Kit: 5 Bottles, 3 ml each	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE TDM1 Test Set 301ri	Kit: 5 Bottles, 3 ml each; 5 bottles, 2 mL each.	3/21/2022
LGC Clinical Diagnostics, Inc	VALIDATE TDM1 Test Set 301vt	Kit: 5 Bottles, 3 ml each	3/21/2022
o2si smart solutions	Custom Pharmaceutical Mixture, 12–0370, 100 ug/mL, 5 × 1 mL (ISO 17034).	1 Package; 5 × 1 mL amber ampules.	1/14/2022
o2si smart solutions	Hydrocodone hydrogen (+)-bitartrate as hydrocodone in acetonitrile Solution, 5,000 mg/L PARENT STOCK SOLUTION—NOT FOR SALE.	Amber ampule: 1 mL	2/11/2022
Restek Corporation	Custom Heroin Standard	Glass ampule: 1.3 mL	3/8/2022
RTI International	12198–62–06	Glass tube: 7 mL	3/1/2022
RTI International	2023 DMPM–01	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 DMPM–02	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 DMPM–03	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 DMPM–05	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 DMPM–06	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 DMPM–07	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 FTC–02	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–03	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–05	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–06	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–07	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–09	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–10	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–11	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–13	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–14	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 FTC–15	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 OFD–01	Vial: 2 mL	3/30/2022

## CHART I—Continued

Supplier	Product name	Form	Application date
RTI International	2023 OFD-02	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-03	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-04	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-05	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-06	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-07	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-08	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-10	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-11	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-12	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-13	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-14	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-15	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-16	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-17	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-18	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-19	Vial: 2 mL	3/30/2022
RTI International	2023 OFD-20	Vial: 2 mL	3/30/2022
RTI International	2023 T-02	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-03	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-04	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-05	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 T-06	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-07	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-08	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-11	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-12	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 T-14	HDPE Bottle: 20 mL	3/30/2022
RTI International	2023 THCB-01	Vial: 10 mL	3/30/2022
RTI International	2023 THCB-02	Vial: 10 mL	3/30/2022
RTI International	2023 THCB-03	Vial: 10 mL	3/30/2022
RTI International	2023 THCB-04	Vial: 10 mL	3/30/2022
RTI International	2023 THCB-05	Vial: 10 mL	3/30/2022
RTI International	2023 THCB-06	Vial: 10 mL	3/30/2022
RTI International	2023 UDS-01	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-02	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-03	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-04	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-05	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-06	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-07	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-08	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-09	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-10	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-11	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-12	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-13	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-14	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UDS-15	HDPE Bottle: 10 mL	3/30/2022
RTI International	2023 UT-01	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-02	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-03	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-05	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-06	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-07	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-08	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-09	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-10	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-11	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-12	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-13	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-14	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UT-15	HDPE Bottle: 50 mL	3/30/2022
RTI International	2023 UTCO-01	HDPE Bottle: 40 mL	3/30/2022
RTI International	2023 ZE-01	Vial: 5 mL	3/30/2022
RTI International	2023 ZE-02	Vial: 5 mL	3/30/2022
RTI International	2023 ZE-03	Vial: 5 mL	3/30/2022
RTI International	2023 ZE-04	Vial: 5 mL	3/30/2022
RTI International	2023 ZE-05	Vial: 5 mL	3/30/2022
RTI International	2023 ZE-06	Vial: 5 mL	3/30/2022
RTI International	2023-OFD-09	Vial: 2 mL	3/30/2022



CHART I—Continued

Supplier	Product name	Form	Application date
RTI International	Sample 1 Matrix: Urine	HDPE tubes: 5 mL	3/7/2022
RTI International	Sample 2 Matrix: Urine	HDPE tubes: 5 mL	3/7/2022
RTI International	Sample 3 Matrix: Plasma	HDPE tubes: 5 mL	3/7/2022
RTI International	Sample 4 Matrix: Urine	HDPE tubes: 5 mL	3/7/2022
RTI International	Sample 6 Matrix: Whole Blood	HDPE tubes: 5 mL	3/7/2022
Thermo Fisher Scientific	Cascadion SM Antiepileptics Internal Standard	Box: 6 vials, 29 mL each	3/24/2022

The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II below is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the

Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II below and specifically described in the application materials received by DEA, are not exempt from application of any

part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters.

CHART II

Supplier	Product name	Form	Application date
Chemtos, LLC	ANPP (1 mg/mL in acetonitrile)	Amber ampule: 1mL	3/14/2022
CPI International	Custom Hormone Mix, 9–072, 1000 mg/L, 6 x 1 ml	1 Package; 6 x 1 mL amber ampules.	1/14/2022
LGC Clinical Diagnostics, Inc	TDM1 ab WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 au WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 bc WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 db WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri GentC Set WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 ri TDM Set WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	TDM1 vt Set WrkBlk—Level 5	Volumetric flask: 200—8000 mL.	3/21/2022
LGC Clinical Diagnostics, Inc	Validate TDM Phenobarbital Stock	Plastic vial: 150 mL	3/21/2022

**Opportunity for Comment**

Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until she may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as she determines appropriate.

**Approved Exempt Chemical Preparations are Posted on the DEA’s Website**

A list of all current exemptions, including those listed in this order, is available on the DEA’s website at [http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt\\_chemlist.pdf](http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf).

The dates of applications of all current exemptions are posted for easy reference.

**Kristi O’Malley,**  
Assistant Administrator.  
[FR Doc. 2022–18794 Filed 8–30–22; 8:45 am]  
BILLING CODE 4410–09–P

**DEPARTMENT OF JUSTICE**

**Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act**

On August 25, 2022, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the District of Utah in the lawsuit entitled *United States v. United Park City Mines Company*, Civil Action No. 2:19–cv–00200–BSJ.

The United States filed this lawsuit against United Park City Mines Company (“UPCM”) under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”). The complaint seeks recovery of costs that the United States incurred pursuant to a 2014 Administrative Settlement Agreement and Order on Consent (“2014 AOC”), along with declaratory judgments regarding UPCM’s liability for future costs to be incurred in responding to releases of hazardous substances at the Richardson Flat Tailings Site near Park City, Utah.

Under the Consent Decree, UPCM agrees to pay or cause to be paid \$6,475,000 for response costs at the Richardson Flat Tailings Site, \$350,000 for natural resource damages at the Richardson Flat Tailings Site, and \$250,000 for response costs at the nearby Uintah Mining District Site. In return, the United States agrees not to sue UPCM and certain other entities